Dopamine injection (Intropin) is used to treat certain conditions that occur when you are in shock, which may be caused by heart attack, trauma, surgery, heart failure, kidney failure, and other serious medical conditions.

Add 3 mL of Cordarone I.V. (150 mg) to 100 mL D5W (concentration = 1.5 mg/mL). Infuse 100 mL over 10 minutes. Followed by Slow: 360 mg over the NEXT 6 hours (1 mg/min).

Cordarone Injection 3ml is used to treat various types of serious irregular heartbeat (arrhythmia) such as fibrillation and tachycardia (increased heart rate). It is an anti-arrhythmic type of medicine which rapidly restores your heart to a steady and regular rhythm.

Amiodarone is incompatible with saline and should be administered solely in 5% dextrose solution. Amiodarone diluted with 5% dextrose solution to a concentration of less than 0.6 mg/ml is unstable. Solutions containing less than two ampoules Amiodarone in 500 ml dextrose 5% are unstable and should not be used.

Dopamine is injected into a vein through an IV. A healthcare provider will give you this injection. Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when dopamine injection is injected.

Betapace and Cordarone belong to different drug classes. Betapace is a beta-blocker and Cordarone is an antiarrhythmic drug.

Cordarone X Intravenous should only be used when facilities exist for cardiac monitoring, defibrillation, and cardiac pacing. Cordarone X Intravenous may be used prior to DC cardioversion. The standard recommended dose is 5mg/kg bodyweight given by intravenous infusion over a period of 20 minutes to 2 hours.

Conclusions: The present study suggests that amiodarone can be administered undiluted without unmanageable haemodynamical side-effects in the treatment of out-of-hospital cardiac arrest. This is likely to save time and simplifies the treatment protocol in the prehospital setting.

Hypotension is the most common adverse effect seen with intravenous amiodarone. In clinical trials, treatment-emergent, drug-related hypotension was reported as an adverse effect in 288 (16%) of 1836 patients treated with intravenous amiodarone.

The recommended starting dose of Cordarone I.V. is about 1000 mg over the first 24 hours of therapy, delivered by the following infusion regimen: 150 mg over the FIRST 10 minutes (15 mg/min). Add 3 mL of Cordarone I.V. (150 mg) to 100 mL D 5 W (concentration = 1.5 mg/mL). Infuse 100 mL over 10 minutes.

Cordarone I.V. should be used for acute treatment until the patients ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but Cordarone I.V. may be safely administered for longer periods if necessary.

Physically compatible, with amiodarone loss <10% at 2 hours at room temperature. Physically compatible, with no amiodarone loss at 24 hours at room temperature. Cordarone I.V. in D 5 W is incompatible with the drugs shown below.

It has a molecular weight of 681.78 and contains 37.3% iodineby weight. Cordarone I.V. is a sterile clear, pale-yellow micellar solution visually free from particulates. Each milliliter of the Cordarone I.V. formulation contains 50 mg of amiodarone HCl, 20.2 mg of benzyl alcohol, 100 mg of polysorbate 80, and water for injection.